In the Original Investigation titled “Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury: A Randomized Clinical Trial,”1 published March 16, 2022, Nastasia James was missing from the list of Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. This article has been corrected.1
1.Puskarich
MA, Ingraham
NE, Merck
LH,
et al; Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. Efficacy of losartan in hospitalized patients with COVID-19–induced lung injury: a randomized clinical trial.
JAMA Netw Open. 2022;5(3):e222735. doi:
10.1001/jamanetworkopen.2022.2735PubMedGoogle ScholarCrossref